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Background: Long non-coding RNAs have been shown to have critical regulatory roles in cancer biology. However,
the contributions of lncRNAs to gastric cancer remain largely unknown.
Methods: The differential expression of lncRNAs in gastric cancer and paired non-cancerous tissues were identified
by microarray and validated using quantitative real-time PCR. Gastric samples from patients with gastric cancer were
further analyzed for levels of a specifically downregulated lncRNA (termed as LEIGC).
Results: We found that there were significantly lower levels of LEIGC expression in cancer tissue than in adjacent
non-cancerous tissues in human gastric cancers (P < 0.01). Overexpression of LEIGC suppressed tumor growth and
cell proliferation, and enhanced the sensitivity of gastric cancer cells to 5-fluorouracil (5-FU), whereas knockdown of
LEIGC showed the opposite effect. We further demonstrated LEIGC functions by inhibiting the epithelial-to-
mesenchymal transition (EMT) in gastric cancer.
Conclusions: Our data suggested that LEIGC is a tumor-suppressing lncRNA in gastric cancer, and led us to propose
that lncRNAs may play important regulatory roles in cancer development and progression.
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Gastric cancer is the fourth leading cause of cancer death,
with a high mortality worldwide, especially in Asia [1,2].
Unfortunately, gastric cancer is difficult to cure unless it is
identified at an early stage, before it has begun to spread.
The 5-year survival rate of gastric cancer patients remains
poor, at approximately 40%, despite recent advances in
surgical techniques and medical treatment [3,4]. Metasta-
sis is the main cause of death from such tumors. Thus,
there is an urgent need to identify new molecular markers
for early diagnosis, prediction of metastatic progression
and prognosis of gastric cancer patients.
The human transcriptome comprises not only large
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unless otherwise stated.but also many non-protein coding transcripts that func-
tion as important regulatory molecules in tumor sup-
pressor or oncogenic pathways [5]. Non-coding RNAs
are divided into short non-coding RNAs and long non-
coding RNAs depending on their length. Long non-
coding RNAs (lncRNAs) are defined as non-coding
RNAs of more than 200 nucleotides in length, and are
characterized by the complexity and diversity of their se-
quences and mechanisms of action [6]. Recent deep
transcriptome sequencing and microarray studies have
revealed that 70–90% of the human genome is estimated
to be transcribed into mostly non-protein-coding RNA
[7]. Increasing evidence indicates that lncRNAs exert
important roles in a wide range of biological processes,
including cell differentiation, chromatin remodeling, im-
mune responses and tumorigenesis [6-8]. LncRNA levels
are strongly associated with aberrant gene expression
that may drive cancer development and progression [9],
such as HOTAIR in non-small cell lung cancer (NSCLC)
[10], PRNCR1 (also known as PCAT8) and PCGEM1 inis is an Open Access article distributed under the terms of the Creative
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meningiomas [12,13]. Thus, differential expression of
lncRNAs may be profiled to aid cancer diagnosis, prog-
nosis and selection of potential therapeutics.
Although lncRNAs play important roles in human dis-
eases, the mechanism through which they contribute to
cancer development is still largely unknown. LncRNAs
can regulate critical cancer pathways at a transcriptional,
post-transcriptional and epigenetic level [14]. Mounting
evidence suggests that a major role of lncRNAs is to act as
modular scaffolds for protein-chromatin interactions [15].
Several lncRNAs can control gene expression by direct re-
cruitment of histone-modifying enzymes to chromatin
[6,15]. Chromatin modification and DNA methylation are
crucial epigenetic events that are fundamentally disturbed
during the development of cancer. LncRNAs can also
affect protein-coding transcript response to different bio-
logical processes [16].
However, there are only preliminary studies on the role
of lncRNAs in gastric cancer [17-19], and the overall patho-
physiological contributions of lncRNAs to gastric cancer re-
main largely unknown. A current estimate of the lncRNA
gene number in the human genome ranges from 8000–
20,000 unique lncRNAs [20,21], suggesting lncRNAs
constitute a large yet undiscovered part of normal cellular
networks that may be disrupted in cancer. Therefore, it is
of great importance to explore the molecular mechanisms
of lncRNAs in gastric cancer development and progression.
In this study, we aimed to investigate the expression pattern
and clinicopathological implications of lncRNAs in gastric
cancer tissues. We identified a new specific differentially-
expressed lncRNA (termed LEIGC), which was downregu-
lated in gastric cancer tissues compared with adjacent
non-cancerous tissues. Then we performed gain- and loss-
of-function studies to determine the effect of LEIGC on
tumor growth, cell proliferation, and migration, and
showed that LEIGC suppressed tumor growth, cell prolif-
eration and EMT in gastric cancer, and increased the sen-
sitivity of gastric cancer cells to 5-FU.
Methods
Cell lines
Human gastric cancer cell lines, MGC-803, AGS, SGC-
7901 were purchased from the cell bank of China Academy
of Medical Science (China). Cells were cultured in RPMI
1640 medium (Gibco, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS, Gibco) and maintained
at 37°C with 5% CO2.
LncRNA expression microarray analysis
Total RNA of gastric cancer tissues and paired normal
tissues were extracted using Trizol reagent (Invitrogen,
Carlsbad, CA, USA) and treated with RNase-free
DNase I (Qiagen, Valencia, CA, USA) according to themanufacturer’s protocol. The quantity and quality of
RNA was evaluated using a Nanodrop spectrophotom-
eter (Thermo Scientific, Worcester, MA, USA). The
lncRNA expression profile of each sample was exam-
ined using a lncRNA expression microarray (SurePrint
Human Gene Expression Microarray Kit, Agilent tech-
nologies, Santa Clara, CA, USA). The BROAD Institute
database was used in the genesis of the array. After
hybridization and washing, the processed slides were
scanned with the Agilent Microarray Scanner (Agilent
technologies Santa Clara, CA, USA). Raw data were ex-
tracted as pair files using Feature Extraction software
10.7 (Agilent technologies). A fold change of ≥ 2.0 or
<0.5 (P ≤ 0.05) was set as a threshold for up- and down-
regulated genes, respectively, and data were presented
as mean ± SD. Raw data were normalized by a Quantile
algorithm using Gene Spring Software 11.0 (Agilent
technologies). Hierarchical clustering was performed
based on differentially-expressed lncRNAs using Cluster
Treeview software from Stanford University.
Structural analysis of LEIGC
We used the BLAT program of the University of California
Santa Cruz (UCSC), Genome Browser, BLAST, and MAP
VIEW of the NCBI to analyze the gene sequence and
chromosomal location of LEIGC.
Quantitative real time PCR analysis
Total RNA from cell lines and tissues was purified by the
Trizol (Invitrogen) method according to the manufac-
turer’s instructions. RNA quantity and quality were evalu-
ated using a Nanodrop spectrophotometer. The RNA was
reverse-transcribed into cDNA using the Reverse Tran-
scriptase M-MLV (Promega, Madison, WI, USA), and the
expression of LEIGC, snail, zeb, slug, CDH1, and twist was
measured using SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) on the Stepone plus
system (Applied Biosystems). Each sample was run in trip-
licate and the gene expression levels were normalized to
GAPDH expression. The primers for quantitative real time
PCR (qRT-PCR) analysis were listed in Table 1.
Cycling conditions were 10 min at 95°C for initial de-
naturation, followed by 40 cycles of 15 sec at 95°C for
denaturation, 30 sec at 60°C for combined annealing and
30 sec at 72°C for primer extension. Each sample was
run in triplicate and the gene expression levels were nor-
malized to that of GAPDH expression.
Establishment of lncRNA or lncRNA-shRNA stable cells
LEIGC vector (LV6-Puro) or LEIGC-shRNA vector (pGLV2-
U6-Puro) (Additional file 1: Figure S1) and scrambled
shRNA or non-related lncRNA vector lentiviral particles
(GenePharma Tech, Shanghai, China) were transfected into
MGC-803 cells. Cells were selected with 5 μg/ml puromycin
Table 1 Primer sequences used in qRT-PCR
Gene name Primers
LEIGC F: 5’- agg ata cgt aag aaa cac ttc tgt -3’
R: 5’- tgt ctt ggt tta aca acc ga -3’
snail F: 5’- acc cca cat cct tct cac tg −3
R: 5’- tac aaa aac cca cgc aga ca −3
slug F:5’- aca cac aca cac cca cag ag −3
R:5’- aaa tga ttt ggc agc aat gt −3
zeb F: 5’- gca caa cca agt gca gaa ga -3’
R: 5’- cat ttg cag att gag gct ga -3’
E-cadherin F: 5’- tgc tct tgc tgt ttc ttc gg-3’
R: 5’- tgc ccc att cgt tca agt ag-3’
N-cadherin F: 5’- tgg atg gac ctt atg ttg ct -3’
R: 5’- aac acc tgt ctt ggg atc aa -3’
twist F: 5’-gga gtc cgc agt ctt acg ag-3’
R: 5’-cca gct tga ggg tct gaa tc-3’
GAPDH F: 5’-ctt agc acc cct ggc caa g-3’
R:5’-gat gtt ctg gag agc ccc g-3’
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The overexpression and knockdown efficiencies were veri-
fied by qRT-PCR.
In vitro motility assay
Transwell insert chambers with 8-μm porous mem-
branes (Corning Incorporated, NY, USA) were used for
motility assays. Cells were washed three times with PBS
and 5 × 104 cells in serum-free media were added to the
top chamber. The bottom chamber was filled with RPMI
1640 medium containing 15% FBS. Cells were incubated
for 24 h at 37°C in 5% CO2. To quantify migrating cells,
cells in the top chamber were removed using a cotton-
tipped swab, and the migrated cells were fixed in metha-
nol and stained with 0.1% crystal violet.
Cell growth assay
Cells were seeded at a density of 3 × 103 cells/well in a 96-
well plate containing 0.2 ml RPMI 1640 medium with 10%
FBS. Then 20 μl MTS (3-[4,5-dimethylthiazol-2-yl] -5-[3-
carboxmethoxy phenyl]-2-[4-sulfophenyl]-2H-tetrazolium
salt) (Promega) reagent was added to each well and the
cells were incubated at 37°C for 4 h. The OD values were
measured at 490 nm on a microplate reader (Bio-Rad,
Hercules, CA, USA) and assessed daily for 7 days.
Colony formation assay
The proliferative ability of cells was tested in colony for-
mation assays. Approximately 300 cells were seeded into
each well of a 12-well plate. After incubation at 37°C for
14 days, the cells were washed twice with PBS, fixed with
methanol and then stained with 0.1% crystal violet. Thenumber of colonies containing more than 300 cells was
counted under a microscope.
Tumorigenesis assay
A total of 1 × 106 cells suspended in 100 μl RPMI 1640 were
implanted into the hindquarters of 4-week-old female
NOD/SCID mice to assess their ability to initiate tumor xe-
nografts. The use and care of experimental animal was ap-
proved by Institutional Animal Care and Use Committee of
Zhejiang Chinese Medical University. Tumors were mea-
sured weekly and their volume calculated as length ×
width ×width/2 [22].
Western blotting
Total protein from cells was lysed using M-PER Mamma-
lian Protein Extraction Reagent (Thermo) supplemented
with a protease inhibitor cocktail (Sigma, St Louis, MO,
USA). Samples were denatured, and equal amounts of
protein were subjected to SDS-PAGE, and then trans-
ferred to nitrocellulose membrane. After blocking with 5%
non-fat milk in TBST for 60 min, membranes were incu-
bated with primary antibody dissolved in 5% bovine serum
albumin in TBST overnight at 4°C. The following primary
antibodies were used: anti-human- E-cadherin (1:2000,
24E10; Cell Signaling Technology, Danvers, MA, USA),
anti-human-Vimentin (1:2000, D21H3; Cell Signaling
Technology), anti-human-Snail (1:1000, C15D3; Cell Sig-
naling Technology), anti-human-Twist (1:1000; Cell Sig-
naling Technology), anti-human-Zeb (1:1000, D80D3; Cell
Signaling Technology), and anti-human-Slug (1:1000, C19G7;
Cell Signaling). Human GAPDH (1:5000; KangChen,
Shanghai, China) was used as an internal reference.
Cell viability assay
MGC-803 cells were transfected with LEIGC vector or
LEIGC shRNA vector and scrambled shRNA or non-
related lncRNA vector, and incubated for 24 h. Then
cells were reseeded in 96-well plates and treated with
5-FU (NanTong Pharmaceutical Factory, China) at dif-
ferent concentrations for 48 h. The cell viability was
determined by the MTT assay: 20 μl of MTT (Sigma)
per well was added and incubated at 37°C for 4 h. The
reaction was stopped by adding 200 μl of dimethyl sulf-
oxide (DMSO) to each well followed by measuring the
absorbance at 570 nm on a microplate reader (Bio-Rad,
USA) for the indicated time periods at 37°C to deter-
mine the individual IC50 values (50% cell growth inhibi-
tory concentrations).
Clinical gastric cancer sample analysis
The study was approved by the Research Ethics Committee
of Zhejiang Medical University, China. Human gastric can-
cer and paired normal tissues were obtained in accordance
with the ethical standards of the institutional committee.
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for the use of clinical specimens in medical research. Speci-
mens were collected between 2007 and 2009 at the Second
Affiliated Hospital, Zhejiang University School of Medicine.
The diagnosis of each case was confirmed independently by
two pathologists. Tumors were staged using the Union
Internationale Contre le Cancer (UICC) staging system
(Table 2).
Statistical analysis
Data are presented as the means ± standard error of the
mean (SEM). All statistical analyses were performed using
SPSS 16.0 software. The qRT-PCR results from paired
clinical samples were analyzed by a two-tail paired Stu-
dent’s t-test and the other results by a two-tail unpaired
Student’s t-test. P values of <0.05 indicated statistical
significance.
Results
Expression of LEIGC in gastric cancer tissues
To identify genes involved in gastric cancer progression,
lncRNA array analysis was performed on total RNA iso-
lated from three gastric cancer samples, and matched peri-
cancerous samples. Microarray analysis detected differentTable 2 Clinicopathological features of gastric cancer
patients
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TNM stage tumor-node-metastasis stage.upregulated and downregulated lncRNAs (Figure 1A). To
select lncRNA for further studies, we applied more strin-
gent filtering criteria: (1) high-expression levels; and (2)
similar expression patterns in different clinical samples.
Results demonstrated there were four significantly down-
regulated lncRNAs (lncRNA: chr2:118381039–118383698,
lncRNA:chr9:21879775–21938825, lncRNA:chr21:367448
04–36953062, lncRNA: chr14:96089622–96112397) and
seven significantly upregulated lncRNA (lncRNA:chr1:898
73237–89890493, lncRNA:chr15:49013058–49023258, lnc
RNA: chr2:216462380–216469880, lncRNA:chr7:226038
25–22730864, lncRNA:chr13: 29222100–29228575, lncR
NA:chr5:12574968–12804473, lncRNA:chr8: 37330594–
37411701) in gastric cancer tissues versus paired normal
tissues (P < 0.05; Figure 1A).The expression levels of se-
lected lncRNAs (P < 0.05; Figure 1B, C) and mRNA (P <
0.05; Figure 1D) were also validated by qRT-PCR analyses
on the same three human gastric cancer tissue samples
and paired non-cancerous tissues. We further examined
lncRNA: chr2:118381039–118383698 expression levels in
35 paired gastric cancer samples and adjacent normal tis-
sues by qRT-PCR. We observed that lncRNA: chr2:11
8381039–118383698 levels were significantly downregu-
lated in gastric cancer tissue samples compared with nor-
mal tissue samples (P < 0.01; Figure 1E); this was named
as LEIGC. These data indicated that LEIGC may be a
probable new target to prevent relapse and metastasis of
gastric cancer.
Structural analysis of LEIGC
We named this lncRNA gene as LEIGC (lower expression
in gastric cancer) according to the human gene nomencla-
ture guideline by the Human Gene Nomenclature Com-
mittee (HGNC) [23]. We found no repetitive naming
compared with other genes in Genbank and EMBO data-
sets by BLAST. Gene sequence analysis by BLAT, BLAST
and MAP VIEW of NCBI revealed that LEIGC was
present in a novel amplicon on chromosome 2 and lo-
cated at 2q14.1 (Figure 2). LEIGC consists of 2659 bp with
two exons (Figure 2).
LEIGC suppresses tumor growth in vitro
To examine the effect of LEIGC overexpression and knock-
down in gastric cell proliferation, we performed MTS and
colony formation assays. MGC-803 cells are a gastric can-
cer cell line with moderate LEIGC expression level, as con-
firmed by qRT-PCR in our study (Figure 3A). We stably
transfected LEIGC vector (LV6-Puro), LEIGC-shRNA vec-
tor (pGLV2-U6-Puro) and their control vector lentiviral
particles into MGC-803 cells. The efficiency of overexpres-
sion and knockdown was verified by qRT-PCR (Figure 3B).
Overexpression of LEIGC in MGC-803 cells markedly re-
duced the number of cell colonies formed (Figure 3E).
When compared with cells transfected with non-related
Figure 1 Alterations in lncRNA expression profiles between gastric tumor tissues and paired adjacent non-tumorous tissues. (A). lncRNA
expression was evaluated by an lncRNA expression microarray. Results from hierarchical clustering showed different lncRNA expression among samples.
“Red” indicates high expression; “green” indicates low expression. (B). Results from qRT-PCR experiments demonstrating downregulated expression of
lncRNAs in three gastric cancer samples. (C). qRT-PCR analysis of lncRNAs selected from microarray results in three gastric cancer samples revealed
upregulated expression. (D). qRT-PCR verification of mRNA selected from microarray results in three gastric cancer samples. (E). Expression of lncRNA LEIGC
in fresh gastric cancer tissues from 35 patients was detected by qRT-PCR. LEIGC levels were normalized to GAPDH and expressed in terms of the threshold
cycle (CT) ratio. Error bars represent the means ± SEM. *P< 0.05; **P< 0.01.
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creased the cell proliferation rate, as measured by MTS
(P < 0.05; Figure 3C). In contrast, LEIGC knockdown in
MGC-803 cells showed the opposite results (P < 0.05;
Figure 3C). These data supported the tumor suppressive
function of LEIGC in gastric cancer cells.LEIGC inhibits migration of gastric cancer cells in vitro
The important process of carcinoma progression is that
dissociated epithelial cells acquire migration and invasive
abilities and can pass through the basement membrane
to distant tissues. To determine whether LEIGC regu-
lates the migratory ability of gastric cancer cells, we
Figure 2 Partial gene sequence and molecular structure map of
LEIGC. Gene sequence was analyzed by BLAT, BLAST and MAP VIEW
programs. Map of LEIGC molecular structure was revealed by the
BLAT program; 1 and 2 indicate different exons.
Figure 3 Growth and colony formation assays of MGC-803 cells follow
with LEIGC-shRNA vector (shRNA) and scrambled shRNA vector (NC1), or LE
control (blank). (A). Basal levels of LEIGC in MGC-803, SGC-7901 and AGS ce
qRT-PCR. (C). Cell proliferation rate was determined by measuring the abso
of MGC 803 cells. *P>0.05.
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a model because of their strong motility. Pooled LEIGC-
overexpressing cells showed a significantly lower migra-
tion potential than LEIGC knockdown cells and controls
in the migration assay (Figure 4).
LEIGC knockdown promotes tumor progression in vivo
We examined the progression potential of LEIGC knock-
down in MGC-803 cells using a NOD/SCID mouse
model. MGC-803 cells transfected with LEIGC-shRNA
or scrambled vectors were subcutaneously injected into
NOD/SCID mice (n = 4). Tumor growth was monitored
by standard caliper measurement in a blinded fashion.
Tumors formed in sites injected with MGC-803 cells
(Figure 5). After 4 weeks, animals were sacrificed for de-
termination of tumor weights. Histopathological examin-
ation demonstrated that MGC-803 cells with or without
LEIGC knockdown generated uniform implanted tu-
mors. As shown in Figure 5B, tumor development was
first visible at 14 days after injection. Tumors of MGC-
803 cells transfected with scrambled vector grew signifi-
cantly slower in comparison with tumors of MGC-803
cells transfected with LEIGC-shRNA vector (P < 0.05;
Figure 5B). In addition, MGC-803 cells transfected with
LEIGC-shRNA vectors generated tumors that were sig-
nificantly larger than those derived from control cells ating overexpression or knockdown of LEIGC. Cells were transfected
IGC vector (lncRNA) and non-related lncRNA vector (NC2), and blank
lls. (B). Knockdown and overexpression of LEIGC was confirmed by
rbance at 490 nm in MTS assays. (D and E). Colony formation assays
Figure 4 Effect of LEIGC knockdown and overexpression on cell migration. (A). MGC-803 cells that had migrated to the bottom chamber
after transfection with blank vector (blank); (B and C). MGC-803 cells that had migrated to the bottom chamber after transfection with shRNA
vector (shRNA) and scrambled shRNA vector (NC1); (D and E). MGC-803 cells that had migrated to the bottom chamber after transfection with
LEIGC vector (lncRNA) and non-related lncRNA vector (NC2); (F). Quantification of different MGC-803 cells that had migrated to the top
chamber *P<0.05.
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knockdown in MGC-803 cells was tumorigenic and re-
sulted in the formation of aggressive tumors that were
well palpable.
LEIGC enhances chemosensitivity to 5-FU in gastric cancer
To determine the effect of LEIGC on the sensitivity to 5-
FU chemotherapeutic agent, cell viability was measured
using the MTT assay. Transfection of MGC-803 cells with
LEIGC vector resulted in significantly decreased cell via-
bility with treatment of 5-FU at 2 and 5 μg/μl (P < 0.05;
Figure 6A) compared with control cells, whereas there
was no obvious change in cell viability at 10 μg/μl.Figure 5 LEIGC knockdown enhanced the tumorigenic potential of ga
LEIGC-shRNA vector cells (shRNA) and scrambled shRNA vector (NC1) when
in NOD/SCID mice subcutaneously injected with MGC-803 cells; 1, 2, 3, and
in vivo. Tumor volumes were measured each week. Error bars represent meTransfection of MGC-803 cells with LEIGC-shRNA vector
resulted in significantly increased cell viability in each of
the 5-FU treatments (2, 5,10 μg/μl) (P < 0.05; Figure 6A).
Next we measured the IC50 values for 5-FU following
LEIGC knockdown in gastric cancer cells (MGC-803,
SGC-7901 and AGS) and control cells. The result showed
LEIGC knockdown cells had the lowest sensitivity to 5-FU
(P < 0.05; Figure 6B).
LEIGC is a novel factor that prevents EMT in gastric cancer
To determine whether LEIGC contributes to tumor metas-
tasis, we performed morphological observations of MGC-
803 cells following LEIGC overexpression and knockdown.stric carcinoma cells in vivo. (A). Exposure of tumors inoculated with
mice were sacrificed. (A). Representative image of xenograft tumors
4 indicate the different mice. (B). Comparison of xenograft formation
ans ± SEM, *P < 0.05.
Figure 6 Effect of LEIGC on gastric cancer cell chemosensitivity to 5-FU. (A). MGC-803 cells were seeded in 96-well plates and treated with
different concentrations of 5-FU for 48 h. Cell viability was measured using MTT assays. (B). IC50 of gastric cancer cells (SGC 7901, MGC-803 and
AGC) transfected with LEIGC-shRNA vector (shRNA) and scrambled shRNA vector (NC1), *P < 0.05.
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shaped and fibroblastic in monolayer cultures, and displayed
a clear transition from cobblestone-like cells to spindle-like
fibroblastic morphology, whereas LEIGC-overexpressing
cells maintained their cobblestone-like phenotype (Figure 7).
This morphological change implied that the LEIGC knock-
down cells had undergone trans-differentiation from epithe-
lial cells to mesenchymal cells.
To confirm that LEIGC knockdown in MGC-803 cells
resulted in a mesenchymal phenotype, we analyzed the
gene expression profiles of LEIGC-overexpressing cells
versus knockdown MGC-803 cells. As shown in Figure 7,
the epithelial cell-related gene CDH1 was significantly
downregulated, whereas several mesenchymal cell
markers (such as snail, slug, zeb, and twist) were signifi-
cantly upregulated in LEIGC knockdown cells compared
with LEIGC-overexpressing cells (Figure 7F). We further
examined EMT-associated protein expression in MGC-
803 cells by western blotting. As shown in Figure 7G,
LEIGC knockdown cells demonstrated lower expression
of E-cadherin and higher expression of Vimentin, Snail,
Slug, Zeb, and Twist. Overexpression of LEIGC showed
the opposite effect. These data indicated that LEIGC was
a potent EMT inhibitor in gastric cancer cells.
Discussion
Over the past few years, hundreds of lncRNAs have been
shown to play important roles in both transcription and
post-transcriptional processes. Studies have reported that
lncRNA dysfunctions are associated with a broad range of
human tumors, including those of metastasis-associated
lung adenocarcinoma transcript 1 (MALAT1), HOX anti-
sense intergenic RNA (HOTAIR), antisense non-coding
RNA in the INK4 locus (ANRIL), and lncRNA-p21 [10,24].
lncRNAs are aberrantly expressed in many types of cancers
[25,26]. However, the potential roles of lncRNAs in human
cancers are not well understood. In this study, we verifiedthat LEIGC was significantly downregulated in gastric can-
cer tissues compared with paired non-cancerous tissues.
Furthermore, our results indicated that LEIGC inhibited
tumor growth, proliferation, migration, and EMT in gastric
cancer cells. Hence, our results also suggest that LEIGC is a
putative tumor/metastasis suppressor in gastric cancer.
Recently, many studies have shown that lncRNAs have
important roles in the regulation of numerous biological
processes in cancer, including tumor proliferation, migra-
tion, angiogenesis, and EMT. Altered expression of lncRNAs
has been documented in different human cancer types,
prompting increased interest in their use as biomarkers for
diagnosis and prognosis as well as potential therapeutic tar-
gets [7]. For example, a study demonstrated that HULC was
significantly overexpressed in gastric cancer cell lines and
gastric cancer tissues compared with normal tissues, and its
overexpression was correlated with distant metastasis and
lymph node metastasis [17]. Knockdown of HULC inhibited
proliferation, invasion and EMT, and promoted cell apop-
tosis in SGC-7901 gastric cancer cells. Recently, increased
levels of HOTAIR in primary breast tumors were shown to
correlate with breast cancer invasiveness and metastasis
[25]. HOTAIR bridges together the PRC2 complex with the
LSD1 H3K4 demethylase complex, and recruits both com-
plexes to target genes to coordinately alter several histone
modifications and enforce gene silencing. The increased ex-
pression of HOTAIR in human gastric cancers was associ-
ated with venous invasion, lymph node metastases and a
lower overall survival rate [9,15].
To explore the exact mechanisms of LEIGC in gastric
cancer, we used gene transfection experiments to overex-
press and silence LEIGC in MGC-803 gastric cancer cells.
The key event for malignant tumor progression is metasta-
sis, which is based on tumor cell migration and invasion.
Metastasis accounts for the majority of gastric cancer-
related mortality, but the mechanism of the metastatic
process in gastric cancer is very complex, and still not
Figure 7 LEIGC inhibited EMT in MGC-803 cells. (A). MGC-803 cells transfected with blank control vector (blank); (B and C). Cells transfected with
LEIGC-shRNA vector (shRNA) and scrambled shRNA vector (NC1); (D and E). Cells transfected with LEIGC vector (lncRNA) and non-related lncRNA vector
(NC2). (F). Effects of LEIGC on the expression of EMT-related genes CDH1, twist, snail, slug, and zeb at the mRNA level were analyzed by qRT- PCR. *P<0.05.
(G). Effects of LEIGC on the expression of EMT-related proteins. After transfection of the cells with different vectors, E-cadherin, Vimentin, Twist, Slug, and
Zeb expression levels were determined by western blotting. GAPDH protein levels served as an internal control.
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critical step to metazoan embryogenesis and in defining
structures during organ development [27]. During the last
decade, a number of studies have associated EMT with can-
cer progression and metastasis in gastric cancer. In our
transwell assay, knockdown of LEIGC dramatically pro-
moted cell migration in gastric cancer cells (Figure 4). We
found LEIGC silencing was associated with features typical
of EMT, including the conversion of the cobblestone-like
epithelial morphology to spindle-shape mesenchymal
morphology, reduced expression of CDH1, and increased
expression of snail, slug, twist and zeb. Consistent with theobserved morphological changes, some hallmark proteins
of epithelial cells were lost or reduced during the transition,
such as E-cadherin. In contrast, the mesenchymal protein
vimentin was upregulated. It is well known that E-cadherin
plays a critical role in the suppression of tumor invasion.
Most epithelial cancers display downregulated or inacti-
vated E-cadherin [28,29]. It has been shown that the restor-
ation of functional E-cadherin suppresses invasion in many
tumor types. Snail, Twist, Slug and Zeb associated with
EMT have all been shown to target E-boxes on the E-
cadherin promoter, repressing its expression [30,31].
We observed that snail, slug, twist and zeb genes and
Han et al. BMC Cancer 2014, 14:932 Page 10 of 11
http://www.biomedcentral.com/1471-2407/14/932corresponding proteins were highly elevated in LEIGC
knockdown cells (Figure 7). However, overexpression of
LEIGC resulted in the opposite effect in MGC-803 cells.
Taken together, these data indicated that LEIGC is a
critical regulator in preventing EMT in gastric cancer.
However, in our study, no significant correlation was
found between LEIGC expression and distant tumor
metastasis or lymph node metastasis in gastric cancer
(data not shown). This might be because of the low
number of gastric patients in our study.Conclusions
In summary, our data provides evidence that may mechan-
istically link the expression of LEIGC to the proliferation
and migration of gastric cancer cells. We demonstrate that
LEIGC functions as a tumor suppressor lncRNA in gastric
cancer by inhibiting EMT, and propose that lncRNAs may
play important regulatory roles in cancer development and
progression. Further analysis and investigation of the mech-
anisms of LEIGC in the molecular etiology of gastric cancer
will provide lncRNA-directed diagnostic and therapeutic
tools against this deadly disease.Additional file
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